Want to see AU:S66 full AI Analyst Report?
Star Combo Pharma Ltd. (S66) AI Stock Analysis
Top Page
Star Combo Pharma Ltd.
(ASX:S66)
The score is driven by attractive valuation (low P/E and dividend yield) and a solid balance-sheet foundation with improving cash flow. Offsetting these positives are weak and volatile recent fundamentals (sharp 2026 revenue and margin deterioration) and momentum indicators that look stretched despite a near-term uptrend.
Star Combo Pharma Ltd. (S66) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 18.90M
- Dividend Yield
- 2.07%
- Average Volume (3M)
- 24.85K
- Price to Earnings (P/E)
- 48.3
- Beta (1Y)
- -0.61
- Revenue Growth
- -15.24%
- EPS Growth
- -92.54%
- Country
- Australia
- Employees
- 30
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Household & Personal Products
Star Combo Pharma Ltd. Business Overview & Revenue Model
Company Description
Star Combo Pharma Limited is involved in the production and supply of health foods and dietary supplements across Australia and China. The company's activities are organized into two primary divisions: Star Combo and Austoyou Retail. It manages the f...
Star Combo Pharma Ltd. Financial Statement Overview
Summary
Strong balance sheet (low leverage and sizable equity base) supports resilience, and cash flow has improved with positive operating and free cash flow in 2025–2026. However, financial performance is held back by sharp 2026 revenue contraction, material margin deterioration (operating profit slightly negative), and earnings volatility after an unusually strong 2025.
Income Statement
48NeutralBalance Sheet
78PositiveCash Flow
63Positive| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.57M | 23.57M | 27.81M | 26.02M | 24.70M | 22.88M |
| Gross Profit | 4.99M | 4.99M | 6.27M | 5.44M | 4.66M | 5.61M |
| EBITDA | 560.35K | 1.24M | 6.99M | 2.24M | -2.53M | -126.71K |
| Net Income | 394.61K | 394.61K | 5.25M | 747.33K | -4.00M | -696.35K |
Balance Sheet | ||||||
| Total Assets | 50.11M | 50.11M | 48.45M | 42.82M | 42.23M | 43.44M |
| Cash, Cash Equivalents and Short-Term Investments | 18.01M | 18.01M | 18.11M | 7.36M | 9.49M | 10.39M |
| Total Debt | 4.19M | 4.19M | 3.93M | 4.03M | 4.19M | 4.12M |
| Total Liabilities | 11.28M | 11.28M | 10.19M | 9.30M | 8.97M | 8.04M |
| Stockholders Equity | 38.83M | 38.83M | 38.08M | 33.32M | 33.09M | 35.41M |
Cash Flow | ||||||
| Free Cash Flow | 822.64K | 822.64K | 11.55M | -1.76M | -851.83K | -7.21M |
| Operating Cash Flow | 3.28M | 3.28M | 11.94M | -316.45K | 1.88M | 87.11K |
| Investing Cash Flow | -2.02M | -2.02M | -9.72M | -136.79K | -3.23M | -3.24M |
| Financing Cash Flow | -940.75K | -940.75K | -795.12K | -370.93K | -53.44K | -169.08K |
Star Combo Pharma Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:S66, the sentiment is Neutral. The current price of 0.14 is below the 20-day moving average (MA) of 0.14, above the 50-day MA of 0.14, and below the 200-day MA of 0.16, indicating a neutral trend. The MACD of 0.00 indicates Positive momentum. The RSI at 56.41 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:S66.
Star Combo Pharma Ltd. Peers Comparison
Overall Rating
- AU:S6669Neutral
AU:NUC46Neutral
AU:HPC41Neutral
AU:EVE38Underperform
AU:HCT29Underperform
AU:NGS26Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:S66 | 69Neutral | AUD 18.90M | 48.27 | 1.02% | 2.07% | -15.24% | -92.54% |
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| AU:NUC | 46Neutral | AUD 12.55M | -1.68 | -88.51% | ― | 11.96% | -81.99% |
| AU:HPC | 41Neutral | AUD 1.61M | -0.37 | -239.37% | ― | ― | ― |
| AU:EVE | 38Underperform | AUD 4.76M | -2.11 | -49.07% | ― | -33.53% | 42.98% |
| AU:HCT | 29Underperform | AUD 12.14M | -3.79 | 1795.70% | ― | 0.72% | -486.96% |
| AU:NGS | 26Underperform | AUD 18.32M | -0.01 | -130.72% | ― | -33.05% | 94.22% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:S66 | Star Combo Pharma Ltd. | 0.14 | -0.07 | -33.33% | |
| AU:EVE | EVE Health Group Limited | 0.01 | -0.02 | -56.67% | |
| AU:NUC | Nuchev Pty Ltd | 0.08 | -0.06 | -42.86% | |
| AU:HCT | Holista Colltech Limited | 0.03 | -0.04 | -57.69% | |
| AU:NGS | Nutritional Growth Solutions Ltd. | 0.02 | -0.00 | -9.52% | |
| AU:HPC | Hydration Pharmaceuticals Co. Ltd. | ― | ― | ― |
Star Combo Pharma Ltd. Corporate Events
Star Combo Pharma Declares Dividend for Year Ended June 2026
Star Combo Pharma Ltd. has announced a dividend distribution to holders of its ordinary fully paid shares, signalling a return of capital to shareholders following the twelve-month period ending 30 June 2026. The payment, set at AUD 0.00296114 per sh...
Star Combo Pharma Files FY2026 Preliminary Final Report
Star Combo Pharma Ltd has released its Appendix 4E Preliminary Final Report for the financial year ended 30 June 2026, providing investors with an overview of its annual performance. The report package includes the directors’ report, full finan...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 26, 2026